NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure

Heart Failure Clinical Trial

— NATRIUM-HF  

Official title:

NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04235062
• Other study ID #: CHF201901
• Status: Completed
• Phase: N/A
• Start date: April 1, 2020
• Est. completion date: April 26, 2021

Study information

• Verified date: April 2022
• Source: Momentum Research, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

NATRIUM-HF is a multicenter, non-randomized, pre-post intervention study designed to assess renal response to intravascular fluid expansion and diuretics after sacubitril/valsartan (Entresto®) in euvolemic heart failure patients with reduced ejection fraction. Approximately 230 eligible patients will attend one visit prior to and visits 2 and 3 months after starting Entresto®. At each visit, the patient's responses to extravascular fluid expansion with Ringer's solution and to a loop diuretic bolus will be measured. Biomarkers measured in blood and urine samples will include natriuretic peptides (NP) B-type NP (BNP) and N-terminal proBNP (NT-proBNP), NP fragments, neprilysin activity and concentration, and other biomarkers related to heart failure.

Description:

NATRIUM-HF is a multicenter, non-randomized, pre-post intervention study designed to assess renal response to intravascular fluid expansion and diuretics after sacubitril/valsartan (Entresto®) in euvolemic heart failure patients with reduced ejection fraction. Ambulatory patients with HFrEF who remain symptomatic despite optimal treatment for more than 3 months with an ACEi or ARB, a beta-blocker and a mineralocorticoid receptor antagonist (MRA) for whom sacubitril/valsartan is indicated and is about to be initiated will be enrolled. Approximately 230 patients will attend three outpatient visits: before, and 2 months and 3 months after initiation of, or switch from treatment with angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) to, oral treatment with the angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril/valsartan (Entresto®). Patient's responses to fluid expansion and diuretic administration will be assessed at each study visit. The same procedures will be followed at each visit. First, baseline vital signs, clinical assessments (dyspnea score, jugular vein distension, peripheral edema score, pulmonary rales), and blood samples will be obtained. Urine will be collected over a period of 3 hours and urine samples will be obtained from the collected urine at the end of the 3-hour collection period, and vital signs and clinical assessments will be obtained. This will be followed by an infusion of 0.5 liter Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution infused in 10 min followed by an infusion of 0.5 liter over 1 hour 50 minutes. Of note 1liter Ringer's contains 8.6 g or 374 mmol of sodium. 1 hour after the end of the infusion, clinical assessments (dyspnea score, jugular vein distension, peripheral edema score, pulmonary rales) and blood samples will be obtained. Urine will be collected over a period of 3 hours and urine samples will be obtained from the collected urine at the end of the 3-hour collection period. After the second set of blood and urine samples are obtained, 40 mg of furosemide will be given IV and blood samples will be obtained thereafter hourly for 3 hours. Urine will be collected over a period of 3 hours and urine samples will be obtained from the collected urine at the end of the 3-hour collection period, and vital signs and clinical assessments will be obtained. Biomarkers measured in blood and urine samples will include natriuretic peptides (NP) B-type NP (BNP) and N-terminal proBNP (NT-proBNP), NP fragments, neprilysin activity and concentration, and other biomarkers related to heart failure. The aim of NATRIUM-HF is to assess the change in natriuretic response to intravascular fluid expansion and diuretics in euvolemic patients with heart failure and reduced ejection fraction (HFrEF) after initiation of, or switch from ACEi/ARB to, sacubitril/valsartan (Entresto®) therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 229
• Est. completion date: April 26, 2021
• Est. primary completion date: April 26, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion criteria:

1. Male or female patients = 18 and < 80 years of age.

2. Ambulatory patients with a diagnosis of stable NYHA class II heart failure with left ventricular ejection fraction <40 %, for whom sacubitril/valsartan (Entresto®) is indicated as recommended by ESC guidelines and are about to be switched to Entresto® therapy.

3. Stable oral doses of ACEi or ARB, beta-blocker, mineralocorticoid antagonist (MRA), and loop diuretic (up to 120 mg daily furosemide or equivalent*) for > 3 months prior to Screening, except where intolerance or contraindication documented.

4. Stable HF without any recent exacerbation of symptoms and/or signs of HF, admission for HF, unplanned clinic visit or emergency service visit for HF or need for significant up titration or new administration of oral or IV diuretics, renin-angiotensin system (RAAS) blockers (including ACEi, ARB, and/or MRA) and/or beta blockers for > 3 months.

5. Euvolemia as defined by no signs of congestion (pulmonary rales or >1+ peripheral edema) by physical examination.

6. Written informed consent to participate in the study.

7. Ability to comply with all study requirements, without major morbidities compromising the patient's ability to participate and understand the study for 90 days.

Exclusion criteria:

1. Significant pulmonary disease contributing substantially to the patients' dyspnea such as FEV1< 1 liter or need for chronic steroid therapy.

2. Myocardial infarction, unstable angina, ICD or CRT implantation, or cardiac surgery, including percutaneous transluminal coronary intervention, within past 3 months.

3. History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device.

4. Sustained ventricular arrhythmia with syncopal episodes within past 3 months that is untreated.

5. Presence of any hemodynamically significant valvular stenosis or regurgitation, except mitral or tricuspid regurgitation secondary to left ventricular dilatation. Presence of hemodynamically significant obstructive lesions of left ventricular outflow tract.

6. Stroke or TIA within the past 3 months

7. Primary liver disease considered to be life threatening.

8. Any episode of symptomatic hypotension within 3 months prior to screening.

9. Known history of angioedema with ACEi or ARB use, or history of hereditary or idiopathic angioedema.

10. Coagulation or bleeding disorder.

11. Systolic blood pressure < 100 mmHg.

12. Serum sodium > 146 mEq/L (146 mmol/L).

13. Serum potassium > 5.2 mEq/L (5.2 mmol/L) or < 3.5 mEq/L (3.5 mmol/L).

14. Renal disease or eGFR < 30 ml/min/1.73m2 (as measured by the simplified MDRD formula).

15. Ultrafiltration or dialysis within 3 months prior to Screening.

16. Hypersensitivity to sacubitril, valsartan, or any of the excipients in Entresto®; or hypersensitivity to furosemide.

17. History or presence of any other diseases (i.e. including malignancies) with a life expectancy of < 3 months.

18. Participation in any CHF trial or any investigational drug or device study within the 30 days prior to Screening.

19. History of noncompliance to medical regimens and patients who are considered potentially unreliable.

20. Pregnant or nursing (lactating) women.

21. Active infection based on abnormal temperature and elevated WBC count.

22. Receipt of blood transfusion within 3 months prior to Screening.

23. Current use of any drug containing a direct renin inhibitor (aliskiren) or neprilysin inhibitor (sacubitril).

• Equivalent oral loop diuretic doses will be considered as 1 mg bumetanide=20 mg torsemide=80 mg furosemide

Related Conditions & MeSH terms

• Heart Failure

Intervention

Drug:
• Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) Solution
A 2-hour of infusion of Ringer's (8.6 g/L sodium chloride, 0.33 g/L calcium chloride, 0.3 g/L potassium chloride) solution will be given following completion of the first 3-hour urine collection period: 0.5 liter infused over 10 min followed by 0.5 liter infused over 1 hour 50 minutes.
• Intravenous Bolus Furosemide
Following completion of the second 3-hour urine collection period and after the second set of blood and urine samples are obtained, 40 mg of furosemide will be given as an IV bolus.

Locations

Country	Name	City	State
Armenia	Erebouni Medical Center CJSC	Yerevan
Armenia	Institute of Cardiology named after L.A. Hovhannisyan	Yerevan
Armenia	Nairi Medical Center	Yerevan
Armenia	Yerevan State Medical University	Yerevan
Bosnia and Herzegovina	University Clinical Center Republic of Srpska, Banja Luka Department of Cardiology	Banja Luka
Bosnia and Herzegovina	University Clinical Center Mostar	Mostar
Russian Federation	Regional budget Healthcare Institution "Cardiological dispensary"	Ivanovo
Russian Federation	Moscow State Budgetary Institution of Healthcare of Moscow "City Clinical Hospital named after V.V. Vinogradov of the Department of Healthcare of Moscow"	Moscow
Russian Federation	State Budgetary Healthcare Institution of Moscow "City clinical hospital #51 of the Department of Healthcare of Moscow"	Moscow
Russian Federation	State Budgetary Healthcare Institution of Moscow "City Clinical Hospital named after V.V. Veresaev of the Department of Healthcare of Moscow"	Moscow
Russian Federation	State Budgetary Healthcare Institution of Moscow "Moscow City Clinical Hospital named after V.M. Buyanov" of the Department of Healthcare of Moscow"	Moscow
Russian Federation	MedFort LLC	Saint Petersburg
Russian Federation	State Budgetary Healthcare Institution of Vladimir region "Vladimir City Hospital # 4"	Vladimir

Sponsors (3)

Lead Sponsor	Collaborator
Momentum Research, Inc.	Abbott, Saint-Louis-Lariboisière University Hospitals

Countries where clinical trial is conducted

Armenia,  Bosnia and Herzegovina,  Russian Federation, 

References & Publications (4)

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. — View Citation

Nijst P, Verbrugge FH, Martens P, Dupont M, Tang WHW, Mullens W. Renal response to intravascular volume expansion in euvolemic heart failure patients with reduced ejection fraction: Mechanistic insights and clinical implications. Int J Cardiol. 2017 Sep 15;243:318-325. doi: 10.1016/j.ijcard.2017.05.041. Epub 2017 May 14. — View Citation

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20. — View Citation

Tuttolomondo A, Pinto A, Di Raimondo D, Corrao S, Di Sciacca R, Scaglione R, Caruso C, Licata G. Changes in natriuretic peptide and cytokine plasma levels in patients with heart failure, after treatment with high dose of furosemide plus hypertonic saline solution (HSS) and after a saline loading. Nutr Metab Cardiovasc Dis. 2011 May;21(5):372-9. doi: 10.1016/j.numecd.2009.10.014. Epub 2010 Mar 25. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Natriuretic response to intravascular volume expansion	The average change in natriuretic response to intravascular volume expansion from before to 2 and 3 months after initiation of sacubitril/valsartan therapy. Natriuretic response is defined as the cumulative sodium excretion over the 3 hours of intravascular volume expansion and follow up.	2 and 3 months
Primary	Natriuretic response to IV diuretic administration	The average change in cumulative natriuresis during the first 3 h following the bolus IV furosemide administration from before to 2 and 3 months after initiation of sacubitril/valsartan therapy.	2 and 3 months
Secondary	Natriuretic peptide (NP) response to intravascular volume expansion	Change from from before to 2 and 3 months after initiation of sacubitril/valsartan therapy in the average change over the 2-hour Ringer's infusion and follow up in plasma NP levels from just prior to the start of the infusion.	2 and 3 months
Secondary	Natriuretic peptide response to IV diuretic administration	Change from before to 2 and 3 months after initiation of sacubitril/valsartan therapy in the average change in NP level from the end of the Ringer's infusion to 3 hours following the bolus IV furosemide administration	2 and 3 months
Secondary	Diuretic response	Change from before to 2 and 3 months after initiation of sacubitril/valsartan therapy in the urine volume excreted over the 3 hours following the bolus IV furosemide administration	2 and 3 months
Secondary	4. Changes in dyspnea as measured by a 1-10 scale in response to intravascular fluid expansion, and diuretic administration	Change from before to 2 and 3 months after initiation of sacubitril/valsartan therapy in the average change from just prior to the Ringer's infusion start to one hour following the 2-hour Ringer's infusion and from just prior to the IV bolus furosemide administration to 3 hours following the bolus IV furosemide administration	2 and 3 months